Table 3 Calculated pharmacological values for coronary artery ring constrictor and relaxation response
Treatment Group | EC50 (nM) | Hill slope | ||||
|---|---|---|---|---|---|---|
5-HT | ACh | SNP | 5-HT | ACh | SNP | |
 Naive | 87.7 ± 26.7 | 103.3 ± 28.7 | 20.0 ± 4.3 | 1.3 ± 0.1 | 1.8 ± 0.2 | 1.1 ± 0.1 |
1 Day Post IT Exposure | ||||||
 Citrate | 105.9 ± 17.1 | 75.6 ± 7.4 | 31.0 ± 5.3 | 1.3 ± 0.1 | 1.7 ± 0.1 | 1.2 ± 0.1 |
 20 nm AgNP | 60.2 ± 8.4 | 132.8 ± 56.8 | 22.0 ± 3.4 | 1.5 ± 0.1 | 1.5 ± 0.1 | 1.1 ± 0.1 |
 110 nm AgNP | 75.5 ± 16.3 | 147.6 ± 51.0 | 28.1 ± 4.8 | 1.4 ± 0.1 | 1.6 ± 0.1 | 1.1 ± 0.1 |
 PVP | 79.5 ± 11.5 | 115.7 ± 30.5 | 20.9 ± 3.4 | 1.4 ± 0.1 | 1.7 ± 0.2 | 1.2 ± 0.1 |
 20 nm AgNP | 95.1 ± 20.1 | 95.3 ± 3.0 | 18.9 ± 3.2 | 1.4 ± 0.1 | 1.5 ± 0.0 | 1.2 ± 0.1 |
 110 nm AgNP | 70.0 ± 10.2a | 147.6 ± 51.0 | 23.0 ± 2.4 | 1.3 ± 0.1 | 1.8 ± 0.2 | 1.1 ± 0.1 |
7 Day Post IT Exposure | ||||||
 Citrate | 799.6 ± 395.9 | 57.4 ± 1.2 | 67.1 ± 33.9 | 1.2 ± 0.4 | 1.5 ± 0.0 | 1.0 ± 0.1 |
 20 nm AgNP | 264.2 ± 74.9 | 112.9 ± 29.0 | 55.7 ± 8.2 | 1.1 ± 0.2 | 1.6 ± 0.2 | 1.1 ± 0.1 |
 110 nm AgNP | 954.6 ± 80.8 | 98.3 ± 11.6 | 59.3 ± 12.5 | 1.1 ± 0.2 | 1.9 ± 0.1 | 1.3 ± 0.3 |
 PVP | 237.7 ± 61.1 | 89.2 ± 25.9 | 48.8 ± 3.6 | 1.1 ± 0.2 | 1.6 ± 0.3 | 1.2 ± 0.1 |
 20 nm AgNP | 140.8 ± 31.3 | 117.5 ± 26.3 | 41.0 ± 3.6 | 1.2 ± 0.2 | 1.5 ± 0.1 | 1.0 ± 0.1 |
 110 nm AgNP | 306.0 ± 70.3a | 110.2 ± 39.4 | 50.7 ± 13.3 | 1.1 ± 0.2 | 1.6 ± 0.2 | 1.2 ± 0.1 |